Regulus Therapeutics (RGLS) Stock Price, News & Analysis

Company Overview

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $1.51 to $1.54
• 50-Day Range: $1.40 to $1.70
• 52-Week Range: $1.08 to $3.79
• Volume: 45,680 shs
• Average Volume: 1.15 million shs
• Market Capitalization: $100.87 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.80
• Consensus Rating: Moderate Buy

Regulus Therapeutics Stock Analysis - MarketRank™

Regulus Therapeutics scored higher than 56% of companies evaluated by MarketBeat, and ranked 491st out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Regulus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Regulus Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Regulus Therapeutics are expected to decrease in the coming year, from ($0.88) to ($1.38) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Regulus Therapeutics is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Regulus Therapeutics is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Regulus Therapeutics has a P/B Ratio of 1.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.65% of the float of Regulus Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Regulus Therapeutics has a short interest ratio ("days to cover") of 4.

Change versus previous month

Short interest in Regulus Therapeutics has recently decreased by 14.63%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Regulus Therapeutics does not currently pay a dividend.

Dividend Growth

Regulus Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.65% of the float of Regulus Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Regulus Therapeutics has a short interest ratio ("days to cover") of 4.

Change versus previous month

Short interest in Regulus Therapeutics has recently decreased by 14.63%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.96

News Sentiment

Regulus Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Regulus Therapeutics this week, compared to 1 article on an average week.

Search Interest

23 people have searched for RGLS on MarketBeat in the last 30 days. This is an increase of 21% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Regulus Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Regulus Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.35% of the stock of Regulus Therapeutics is held by insiders.

Percentage Held by Institutions

92.38% of the stock of Regulus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RGLS Stock Analysis - Frequently Asked Questions

How have RGLS shares performed this year?

Regulus Therapeutics' stock was trading at $1.28 at the start of the year. Since then, RGLS shares have increased by 19.5% and is now trading at $1.5301.
View the best growth stocks for 2024 here.

How were Regulus Therapeutics' earnings last quarter?

Regulus Therapeutics Inc. (NASDAQ:RGLS) released its quarterly earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by $0.03.

When did Regulus Therapeutics' stock split?

Shares of Regulus Therapeutics reverse split on the morning of Wednesday, June 29th 2022. The 1-10 reverse split was announced on Wednesday, June 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Regulus Therapeutics' major shareholders?

Regulus Therapeutics' top institutional shareholders include NEA Management Company LLC (9.87%), Geode Capital Management LLC (1.96%), State Street Corp (1.53%) and Point72 Asset Management L.P. (1.36%). Insiders that own company stock include Joseph P Hagan, Kathryn J Collier, Crispina Calsada and Denis Drygin.
View institutional ownership trends.

How do I buy shares of Regulus Therapeutics?

Shares of RGLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Regulus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Regulus Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), ServiceNow (NOW) and Eli Lilly and Company (LLY).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 12/24/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:RGLS
• CUSIP: 75915K10
• CIK: 1505512
• Web: www.regulusrx.com
• Phone: (858) 202-6300
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $10.80
• High Stock Price Target: $28.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +605.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-30,040,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -53.07%
• Return on Assets: -48.58%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.15
• Quick Ratio: 14.14

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.05 per share
• Price / Book: 1.46

Miscellaneous

• Outstanding Shares: 65,500,000
• Free Float: 62,651,000
• Market Cap: $100.22 million
• Optionable: Optionable
• Beta: 1.61